The current study was able to address some of these problems by side-by-side analysis of the NCCTG N9831 and NSABP B-31 clinical trials using the same chemotherapy and trastuzumab regimen in patients with high-risk early HER2+ breast cancer. The gene discussed is ERBB2; the disease is breast cancer.